Bavarian Nordic, Helmholtz Zentrum Muenchen GmbH infectious news

Bavarian Nordic said the International Chamber of Commerce International Court of Arbitration ruled in favor of Bavarian Nordic in a dispute in which former partner Helmholtz Zentrum claimed rights to receive royalties to Bavarian Nordic's MVA-BN vaccines, including small pox vaccine Imvamune, under 1994 and 1997 deals. The deals, which ended in 2001, granted Bavarian Nordic an exclusive license to specific Helmholtz patents on recombinant vaccines. The tribunal ruled that Helmholtz Zentrum's claims were baseless and that the MVA-BN technology has been solely created by Bavarian Nordic (see BioCentury, Sept. 7, 2009). ...